Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc.

Overview
Date Founded

2018

Headquarters

100 Campus Drive, Suite 102, Florham Park, NJ, 07932, USA

Type of Company

Public

Employees (Worldwide)

25

Industries

Pharmaceuticals
Biotechnology
Wholesale: Consumer Non-Durables/Sundries

Company Description

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. It focuses on its vonoprazan product, an oral small molecule potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Executives & Employees

Chief Scientific Officer & Co-Founder

Co-Founder

Co-Founder

Director, Chief Executive Officer & President

Chief Financial & Accounting Officer

Chief Commercial Officer

Strategic Advisor

Board of Directors

Co-Founder at Outpost Medicine LLC

Managing Partner, Life Sciences Team at Frazier Healthcare Partners

Former Chief Financial Officer at BevMo Holdings LLC

Chief Executive Officer at Cerecor, Inc.

Former General Manager-Screening at EXACT Sciences Corp.

Director, Chief Executive Officer & President at Phathom Pharmaceuticals, Inc.

Former Senior Vice President & Head-Gastrointestinal Therapeutic Area Unit at Takeda Pharmaceutical Co., Ltd.

Paths to Phathom Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Phathom Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

RA Capital Management, LLC (“RA Capital”) is a crossover fund manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with minimal capital concerns from inception through commercialization.

Details Hidden

PMAM seeks to find securities that are under-valued in the marketplace based on both a relative value analysis of individual securities combined with an analysis of macro-economic factors. The firm invests primarily in investment grade, fixed income securities. Through the combination of a top-down and bottom-up decision-making approach, the team seeks to capitalize upon technical and fundamental dynamics that impact fixed income markets and exploit market inefficiencies. PMAM aims to opportunistically purchase securities to take advantage of inefficiencies of prices in the securities markets. They sell a security when they believe that the security has been fully priced. The firm seeks to reduce credit risk by diversifying among many issuers and different types of securities.

Details Hidden

Summit Rock Advisors aims to preserve their client’s capital, reduce volatility and increase long-term purchasing power over time. The firm seeks to strike this balance, and mitigate unnecessary risk, by achieving adequate diversification by investment strategy, manager, geography, sector and vintage year. Their investment process includes quantitative and qualitative manager research, portfolio construction considerations and a variety of Operational Risk Management (ORM) processes.

Recent Transactions
Details Hidden

Phathom Pharmaceuticals, Inc. issued USD Common Stock

Details Hidden

Phathom Pharmaceuticals, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Transaction Advisors
Escrow Agent

Advised onPhathom Pharmaceuticals, Inc. issued USD Common Stock

Underwriter

Advised onPhathom Pharmaceuticals, Inc. issued USD Common Stock

Underwriter

Advised onPhathom Pharmaceuticals, Inc. issued USD Common Stock

Key Stats and Financials As of 2019
Market Capitalization
$1.07B
Total Enterprise Value
$550M
Earnings Per Share
$-10.32
Debt TEV
0.04x
TEVNet Income
-2.16x
Total Equity
$228M
Total Debt
$23.6M
EBITDA
$-27.3M
Net Profit
$-255M
Revenue
$0
Investors
Details Hidden

RA Capital Management, LLC (“RA Capital”) is a crossover fund manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with minimal capital concerns from inception through commercialization.

Details Hidden

Richard King Mellon Foundation is a grant making foundation. They focus on programs that prioritize conservation, regional economic development, education and human services in the pennsylvania area. The organization was founded in 1947 and is headquartered in Pittsburgh, PA.

Details Hidden

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Takeda's ethical drugs are marketed in around 100 countries worldwide.

Suppliers
Takeda Pharmaceutical Co., Ltd. Chemicals | Osaka, Japan

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Takeda's ethical drugs are marketed in around 100 countries worldwide.

Competitors
Sihuan Pharmaceutical Holdings Group Ltd. Pharmaceuticals - Beijing, China

Founded in 2001, Sihuan Pharmaceutical Holdings Group Ltd. has achieved sound development for 11 years and has grown into the ninth biggest pharmaceutical company in China’s prescription drug market. The Group is also the largest cardio-cerebral vascular prescription drug franchise by market share. The success of the Group can be attributed to its differentiated and proven sales and marketing model, diversified portfolio of market leading drugs, extensive nationwide distribution network and strong research and development capabilities.

Ironwood Pharmaceuticals, Inc. Pharmaceuticals - Cambridge, Massachusetts

At Ironwood, we seek to transform knowledge into medicines that make a difference for patients. Patients shape our business. They influence our drugmaking process, helping us to understand and address their unmet medical needs, whether we’re creating a new medicine or tackling the equally challenging task of delivering that medicine to people around the world. Our employees shape our success. Since our founding in 1998, each of our employees has held shares in the company. Being owners of Ironwood means we are all careful stewards of our resources: we take a data-driven approach in which we celebrate definitive answers – whether those answers support holding steady or changing course – and we challenge every program to earn its way forward. Our discovery and development processes have generated a product that’s approved in the United States and in the European Union, as well as a robust pipeline. As we continue to do drugmaking well, we hope to inspire the support of our shareholders and earn the right to do it again – building an enduring pharmaceutical company that understands and addresses people’s needs.

Kolmar Korea Co., Ltd. Personal Products - Sejong, South Korea

Kolmar Korea Co., Ltd. engages in the original design manufacturing and original equipment manufacturing of cosmetics and pharmaceuticals. It operates through the following business areas: Cosmetics, Pharmaceuticals and Health Functional Foods. The Cosmetics business offers skin care, make up, perfume, quasi drugs, hair care and body care. The Pharmaceuticals business provides specialized medicines, general medicines, bio-equivalence medicine, contract process and quasi drugs. The Health Functional Foods business offers functional health foods, new material development, special foods and other individual sectors. The company was founded on May 15, 1990 and is headquartered in Sejong, South Korea.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Phathom Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Phathom Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Phathom Pharmaceuticals, Inc..